CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use

Share

Program Content

  • HR+/HER2- Breast Cancer
    CDK4/6 Inhibitors in HR+/HER2- Breast Cancer: Addressing Barriers to Their Optimal Use
    Slideset
    Congratulations: You achieved a completion on 04/09/2022
    View Activity

Supporters

Lilly